Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials

PURPOSE: Several ramucirumab trials have reported a higher incidence of selected adverse events (AEs) in East Asian (EA) patients with cancer versus non-EA patients. A meta-analysis was conducted across six completed phase III trials to establish the safety parameters of ramucirumab in EA compared w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Chia-Jui, Muro, Kei, Kim, Tae-Won, Kudo, Masatoshi, Shih, Jin-Yuan, Lee, Keun-Wook, Chao, Yee, Kim, Sang-We, Yamazaki, Kentaro, Sohn, JooHyuk, Cheng, Rebecca, Zhang, Yawei, Binder, Polina, Mi, Gu, Orlando, Mauro, Chung, Hyun Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223521/
https://www.ncbi.nlm.nih.gov/pubmed/30085888
http://dx.doi.org/10.1200/JGO.17.00227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223521/
https://www.ncbi.nlm.nih.gov/pubmed/30085888
http://dx.doi.org/10.1200/JGO.17.00227

Ejemplares similares